ASX Announcement
17 August 2026

Notice of General Meeting

In accordance with ASX Listing Rule 3.17, attached are the following documents:

1. Notice of General Meeting;
2. Proxy Form; and
3. Access Letter to Shareholders.

This announcement is authorised by the Company Secretary of Tissue Repair Limited.

--END-

About Tissue Repair
Tissue Repair Limited (ASX:TRP) is a Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987®, with a secondary focus on commercialising TR Pro+® a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures, as well as other acute wound products in its pipeline. The Company's longer-term strategy is to commercialise its propriety Glucoprime® API to treat a variety of wounds and skin conditions.

TISSUE REPAIR

Notice of General Meeting of Members

Notice is hereby given that a general meeting (**General Meeting** or **Meeting**) of the members of Tissue Repair Limited (ACN 158 411 566) (**Company**) will be held as a physical meeting at:

Location:	Level 5, Automic Group, 126 Phillip Street, Sydney NSW 2000
Date:	18 September 2026
Start time:	10.00am (AEST)
Reason for meeting	The purpose of the Meeting is to consider and, if thought fit, approve: • by **special resolution**, the removal of the Company from the official list of the ASX; and • by **ordinary resolution**, an off-market equal access share buy-back of up to $1,000,000 at a price of $0.13 per share.

Tissue Repair Limited
ACN (158 411 566)
(Company)

1. Business

The purpose of the Meeting is to consider and, if thought fit, to pass the resolutions set out below.

2. Resolutions

Resolution 1 – Approval of Removal from ASX Official List

To consider and, if thought fit, pass the following resolution, with or without amendment, as a **special resolution**:

"*That, pursuant to and for the purposes of ASX Listing Rule 17.11 and for all other purposes, the removal of the Company from the official list of ASX (**Delisting**) be approved on the terms and conditions set out in the Explanatory Statement accompanying this Notice of Meeting, with the Delisting to take effect on a date determined by ASX that is not earlier than one month after the date on which this resolution is passed.*"

Resolution 1 is a **special resolution** and will be passed only if at least 75% of the votes cast by Shareholders entitled to vote on the resolution are cast in favour of the resolution.

Resolution 2 – Approval of Off-Market Equal Access Share Buy-Back

To consider and, if thought fit, pass the following resolution, with or without amendment, as an **ordinary resolution**:

"*That, conditional upon Resolution 1 being passed, pursuant to and for the purposes of Part 2J.1 of the Corporations Act 2001 (Cth) (**Corporations Act**) and for all other purposes, shareholders approve the Company conducting an off-market equal access share buy-back (**Buy-Back**), on the terms and conditions set out in the Explanatory Statement accompanying this Notice of Meeting.*"

Resolution 2 is an **ordinary resolution** and will be passed only if more than 50% of the votes cast by Shareholders entitled to vote on the resolution are cast in favour of the resolution.

Dated: 14 August 2026
By order of the Board

Alistair McKeough
Chairman

Tissue Repair Limited
ACN (158 411 566)
(Company)

Explanatory Statement

This Explanatory Statement has been prepared for the information of shareholders of the Company in connection with the business to be conducted at the General Meeting to be held on 18 September 2026.

The purpose of this Explanatory Statement is to provide shareholders with information that the board of directors of the Company (**Board**) considers material to deciding whether or not to vote in favour of the resolutions set out in the Notice of Meeting.

This Explanatory Statement forms part of, and should be read together with, the Notice of Meeting. Shareholders should read the Notice of Meeting and this Explanatory Statement in their entirety before deciding how to vote.

Terms defined in the Notice of Meeting have the same meaning when used in this Explanatory Statement.

1. Resolution 1 – Approval of Removal from ASX Official List

The Company is currently listed on ASX. On 22 July 2026, the Company announced that it had applied to ASX for removal from the official list of ASX (**Official List**) in accordance with ASX Listing Rule 17.11 (**Delisting**).

ASX has advised the Company that it is likely to approve the Delisting, subject to the Company satisfying certain conditions, including obtaining shareholder approval by special resolution.

Further information regarding the Delisting, including the reasons for the Delisting, the advantages and disadvantages of the Delisting and the consequences of the Delisting, is set out below.

1.1 Why shareholder approval is being sought

ASX has advised the Company that it is likely to approve the Delisting, subject to the Company satisfying certain conditions, including obtaining shareholder approval for the Delisting by way of a special resolution.

Resolution 1 is therefore being put to shareholders because shareholder approval is a condition imposed by ASX under ASX Listing Rule 17.11 and ASX Guidance Note 33 – Removal of Entities from the ASX Official List.

The Board is seeking shareholder approval to satisfy this condition and to provide shareholders with an opportunity to determine whether the Company should proceed with the Delisting.

1.2 Reasons for the proposed Delisting

The Board has carefully considered the costs and benefits of maintaining the Company's ASX listing and has concluded that the Delisting is in the best interests of the Company and its shareholders for the following reasons:

- **Limited liquidity and utility of listing:** The Company's ASX listing has not provided an effective mechanism for liquidity or price discovery. In the 90-day period prior to 22 July 2026, the average daily trading value in the Company's shares was approximately $6,000, indicative of the absence of an active trading market. The limited trading volume means that relatively small trades can have a disproportionate impact on the Company's share price, impairing its reliability as a measure of the Company's underlying value. The Board also considers that the Company's current market capitalisation does not adequately reflect the underlying value of its net assets, strategic position and long-term potential;

- **Concentrated shareholding profile:** The Company's share register is relatively concentrated, comprising a small core group of long-term shareholders and a large number of smaller shareholders. This reduces free float and limits the effectiveness of the ASX listing as a liquidity mechanism;

- **Significant number of small shareholders:** The Company has a material number of shareholders holding unmarketable parcels. These shareholders represent a material proportion of the shareholder base but hold only a small proportion of the Company's issued capital. The Board considers that the ASX listing provides limited practical benefit to many of these shareholders. The Company intends to implement the Buy-Back as a mechanism to provide shareholders with an opportunity to realise value for their Shares and, following completion of the Buy-Back, an unmarketable parcel facility in accordance with the Company's constitution (**Unmarketable Parcel Facility**); and

- **Cost and administrative burden:** The Board estimates that the Company incurs approximately $800,000 per annum in costs associated with maintaining its ASX listing. An indicative breakdown of those costs is set out below:

Category	**Annual Cost ($)**
ASX listing fee	$36,676
Legal and external compliance advice	$22,549
Share registry and investor relations	$16,829
Audit and financial reporting costs attributable to listed entity requirements	$99,804
Directors' and officers' insurance attributable to listed entity requirements	$66,627
Governance, compliance and administration	$244,797
Management time and internal resources	$239,549
Total	$726,829

The Board considers that these costs, together with the management time and administrative resources required to maintain the Company's ASX listing, are disproportionate having regard to the Company's size, market capitalisation, trading volumes and shareholder profile. If the Delisting proceeds, the Company expects to realise substantial savings in these costs, although some governance, reporting and compliance costs will continue as the Company will remain an unlisted public company.

- **Strategic flexibility:** Operating as an unlisted public company will provide greater flexibility to focus on execution of the Company's business plan and long-term value creation without the short-term market pressures associated with being listed. The Board also considers that this may position the Company to re-engage with public markets in the future under more favourable conditions should that be considered appropriate.

1.3 ASX conditions for the Delisting

The Company has formally applied to ASX for its Delisting.

ASX has provided in-principle advice that it is likely to approve the Delisting, subject to the Company satisfying certain conditions, including:

- the Company obtaining the approval of shareholders for the Delisting by way of a special resolution;
- the Delisting not taking place any earlier than one month after shareholder approval has been obtained;
- the Company including in this Notice of Meeting and the accompanying Explanatory Statement all information necessary to enable shareholders to make an informed decision regarding the Delisting, including:
    - the time and date at which the Company will be removed from the Official List if approval is given;
    - that, if shareholders wish to sell their Shares on ASX, they will need to do so before the Company is removed from the Official List; and
    - the arrangements that will apply after Delisting to enable shareholders to dispose of their Shares and how those arrangements may be accessed;
- the Company complying with any additional information requirements specified by ASX Guidance Note 33 – Removal of Entities from the ASX Official List;
- the Company applying for its shares to be suspended from quotation at least two business days prior to the proposed Delisting date; and
- the Company releasing the full terms of ASX's decision to the market.

The Company intends to comply with and satisfy each of these conditions.

Subject to shareholder approval of Resolution 1 and satisfaction of the conditions imposed by ASX, the Company expects to be removed from the Official List in late November 2026. Shares are expected to be suspended from quotation on ASX at least two business days prior to the expected Delisting date.

The requirement that the Delisting does not take place any earlier than one month after shareholder approval is intended to ensure that shareholders have an adequate opportunity to sell their Shares on ASX should they wish to do so prior to the Delisting.

1.4 Consequences of the Delisting for shareholders - What happens if Resolution 1 is passed?

If Resolution 1 is approved and the Company is removed from the Official List:

- Shares will cease to be quoted on ASX, and shareholders will no longer be able to buy or sell shares on ASX. Shareholders who wish to sell their shares on ASX will need to do so before the shares are suspended from quotation and the Delisting takes effect;
- Shareholders whose holdings are maintained through CHESS will have those holdings converted to holdings on the Company's issuer sponsored sub-register maintained by the Company's share registry. No action will be required by shareholders to effect this conversion;
- There will be no public market for shares following the Delisting. Shareholders who retain their shares following the Delisting will only be able to sell their shares by way of private off-market transactions in accordance with the Company's constitution and the Corporations Act. The Company does not intend to list its securities on any other securities exchange and cannot provide any assurance that a liquid market will exist for shares following the Delisting;
- Following the Delisting, the Company will no longer be subject to the ASX Listing Rules or the ASX Corporate Governance Principles and Recommendations;
- The Company will, however, continue to be subject to the Corporations Act, including:
  - the Company will become an unlisted disclosing entity and, for so long as it has at least 100 members, remain subject to the continuous disclosure obligations under section 675 of the Corporations Act; and
  - the takeover provisions in Chapter 6 of the Corporations Act for so long as the Company has more than 50 members.
- The Company's constitution will remain in effect following the Delisting and shareholders will continue to have the right to:
  - exercise the voting rights attaching to their shares;
  - receive notices of meetings and other communications issued by the Company; and
  - receive any dividends declared by the Company from time to time.
- As an unlisted public company, the Company will no longer have access to certain fundraising mechanisms available to listed entities and future capital raisings will need to be undertaken in accordance with the requirements of the Corporations Act.

1.5 What happens if Resolution 1 is not passed?

ASX Listing Rule 17.11 provides that an entity may only be removed from the official list of ASX if the removal is approved by ASX and approved by a special resolution of the entity's ordinary security holders.

Accordingly, if Resolution 1 is not passed:

- the Company will remain listed on ASX and the Delisting will not proceed;
- the Company's Shares will continue to be quoted on ASX and shareholders will continue to be able to buy and sell Shares on ASX
- the Company will continue to be subject to the ASX Listing Rules and the ASX Corporate Governance Principles and Recommendations, including the reporting, disclosure, corporate governance and other compliance obligations applicable to ASX-listed entities, together with the costs associated with maintaining an ASX listing;
- the Company's Shares will not be removed from CHESS and shareholders whose holdings are maintained through CHESS will continue to hold their Shares through CHESS in the ordinary course; and
- Resolution 2 (Approval of Off-Market Equal Access Share Buy-Back), which is conditional on Resolution 1 being passed, will not proceed.

1.6 Arrangements to provide liquidity for shareholders

The Board recognises the importance of providing shareholders with opportunities to realise value for their Shares in connection with the proposed Delisting.

Accordingly, shareholders may:

- sell Shares on ASX before suspension and Delisting;
- participate in the proposed Buy-Back described in Resolution 2; and
- participate in the proposed Unmarketable Parcel Facility, which the Company intends to implement following completion of the Buy-Back in accordance with clause 3.9 of its constitution.

Following Delisting, shareholders who retain their Shares will only be able to transfer them through private off-market transactions.

The Company cannot provide any assurance that an active or liquid market for shares will exist following Delisting.

1.7 Advantages of the Delisting

The Board considers that the Delisting will provide the following advantages to the Company and its shareholders:

- **Reduced costs:** The Company expects to achieve material cost savings by ceasing to maintain its ASX listing. The Board estimates that the costs associated with maintaining the

Company's ASX listing are approximately $800,000 per annum, including listing fees, compliance, legal and administrative expenses;

- **Greater management focus:** The Delisting is expected to reduce the time and resources devoted to compliance and administrative matters associated with maintaining an ASX listing, allowing management to focus more effectively on the Company's operational and development activities;

- **Strategic flexibility:** Operating as an unlisted public company will provide greater flexibility to focus on execution of the Company's business plan and long-term value creation without the short-term market pressures associated with being listed; and

- **Focus on underlying value:** The Board considers that the Company's limited trading volumes and current market capitalisation do not adequately reflect the underlying value of the Company. The Delisting will allow the Company to focus on long-term value creation rather than short-term market pricing.

1.8 Disadvantages of the Delisting

The Board acknowledges that the Delisting may have the following disadvantages for shareholders:

- **Loss of an established market:** Following the Delisting, shareholders will no longer be able to buy or sell shares on ASX and there will be no public market for the shares. Shareholders who wish to realise value for their shares after the Delisting may find it more difficult to do so and may need to identify potential purchasers privately;

- **Reduced liquidity:** Shareholders who retain their shares following the Delisting will only be able to sell their shares by way of private off-market transactions. There is no assurance that an active or liquid market for shares will exist following the Delisting and shareholders may not be able to dispose of their shares at a time or price they consider appropriate;

- **ASX Listing Rules will cease to apply:** Following the Delisting, the Company will no longer be subject to the ASX Listing Rules or the ASX Corporate Governance Principles and Recommendations. Shareholders will no longer receive the benefit of various protections and governance requirements that apply to listed entities under those regimes;

- **More limited access to capital markets:** As an unlisted public company, the Company will no longer have access to certain fundraising mechanisms available to listed entities and future capital raisings will need to be undertaken in accordance with the Corporations Act. This may reduce the Company's flexibility in accessing capital compared to a listed company; and

- **Reduced transparency regarding market value:** Shareholders who retain their shares may find it more difficult to determine the market value of their investment following the Delisting, as there will no longer be a quoted market price for the shares and any transfer of shares will occur through private transactions.

1.9 Voting exclusion

ASX has not imposed any voting exclusion in respect of Resolution 1. Accordingly, all shareholders will be entitled to vote on Resolution 1.

1.10 **Shareholder remedies**

- **Part 2F.1 of the Corporations Act:** Where a shareholder considers that the Delisting is contrary to the interests of shareholders as a whole, or oppressive to, unfairly prejudicial to, or unfairly discriminatory against a shareholder or shareholders, that shareholder may apply to the Court for relief under Part 2F.1 of the Corporations Act. The Court may make any order under section 233 of the Corporations Act that it considers appropriate in relation to the Company, including orders regulating the conduct of the Company's affairs or requiring the Company to be wound up; and

- **Part 6.10 Division 2 Subdivision B of the Corporations Act:** Where a shareholder considers that the Delisting involves unacceptable circumstances, the shareholder may apply to the Takeovers Panel for a declaration of unacceptable circumstances and orders under Part 6.10 Division 2 Subdivision B of the Corporations Act. If the Takeovers Panel declares circumstances to be unacceptable, it may make any order it considers appropriate to protect the rights and interests of affected persons or to ensure that a takeover or other control transaction proceeds in an efficient, competitive and informed market.

Directors' Recommendation: *The Directors unanimously recommend that shareholders vote in favour of Resolution 1.*

2. Resolution 2 – Approval of Off-Market Equal Access Share Buy-Back

2.1 Background to and reasons for the Buy-Back

The Board has considered the importance of providing shareholders with a reasonable and orderly opportunity to realise value for their shares in connection with the proposed Delisting.

Accordingly, subject to shareholder approval of Resolution 2, the Company proposes to undertake an off-market equal access share buy-back (**Buy-Back**) in accordance with Part 2J.1 of the Corporations Act.

The Board considers that the Buy-Back is an appropriate mechanism to provide shareholders with a structured and orderly opportunity to realise some or all of their investment in the Company prior to the Delisting.

The Board considers that this is particularly important given the limited liquidity of the shares on ASX and the absence of a public market that will exist following the Delisting.

The Buy-Back will only proceed if Resolution 2 is approved by shareholders.

2.2 Key terms of the Buy-Back

Subject to shareholder approval of Resolution 2, the key terms of the Buy-Back are expected to be as follows:

Term	Details
Structure	Off-market equal access share buy-back under Part 2J.1 of the Corporations Act. Eligible shareholders may tender up to 100% of their Shares.
Eligibility	All shareholders registered on the Company's share register as at the Buy-Back Record Date, subject to applicable legal and regulatory restrictions.
Buy-Back price	$0.13 per Share. This represents a premium to the 90-day VWAP of approximately $0.11 per Share prior to 22 July 2026.
Maximum size	Up to $1,000,000 in aggregate, representing approximately 12% to 13% of the Company's issued capital.
Funding	Funded from the Company's existing cash reserves.
Scale-back	If acceptances exceed the maximum buy-back amount, acceptances will be scaled back on a pro rata basis across participating shareholders in accordance with the equal access requirements of the Corporations Act.
Buy-Back Record Date	Expected to be end of September. Shareholders registered on the Company's share register at the Buy-Back Record Date will be entitled to participate in the Buy-Back, subject to applicable legal and regulatory restrictions.
Participation	Eligible shareholders may elect to participate in respect of some or all of their shares. Certain foreign shareholders may not be eligible to participate. Further details will be set out in the Buy-Back offer booklet.

Offer period	The Buy-Back is expected to remain open for approximately four weeks following commencement.
Payment Date	Expected to occur in end of October 2026.
Cancellation of shares	Shares bought back under the Buy-Back will be cancelled following completion of the Buy-Back in accordance with the Corporations Act.

2.3 Participation in the Buy-Back

If Resolution 2 is approved, the Company will dispatch a Buy-Back offer booklet to eligible shareholders setting out the detailed terms of the Buy-Back, including instructions regarding how shareholders may elect to participate.

Participation in the Buy-Back will be voluntary. Eligible shareholders may elect to participate in respect of some or all of their Shares, subject to the terms of the Buy-Back.

2.4 Scale-Back

The Buy-Back is limited to a maximum aggregate amount of $1,000,000. If valid acceptances exceed that amount, acceptances will be scaled back on a pro rata basis across participating shareholders in accordance with the terms of the Buy-Back and the equal access requirements of the Corporations Act.

Accordingly, shareholders may not have all Shares tendered by them accepted under the Buy-Back.

2.5 Non-Participation by certain major shareholders

The Company has received written undertakings from Tony Charara and Peter Scutt (each a director of the Company), together with certain of their associated entities, including Spark Capital Pty Limited and Creight Investments Pty Ltd, that they will not participate in the Buy-Back. Those undertakings are irrevocable and may not be amended, varied, withdrawn, terminated or released without the prior written consent of ASX.

The Board considers that the non-participation of these major shareholders will maximise the opportunity for other shareholders to participate in the Buy-Back and realise value for their Shares.

Given that the Buy-Back is capped at a maximum aggregate amount of $1,000,000, participation by large shareholders could materially reduce the number of Shares available to be bought back from other shareholders through the operation of the scale-back provisions.

Accordingly, the Board considers that the decision of Mr Charara and Mr Scutt, and their respective associated entities, not to participate in the Buy-Back will assist in ensuring that a greater proportion of the Buy-Back capacity is available to other shareholders.

2.6 Effect of the Buy-Back

Shares bought back under the Buy-Back will be cancelled in accordance with the Corporations Act.

The precise number of shares bought back will depend on the level of shareholder participation and any scale-back that may be required.

Shareholders who participate in the Buy-Back will receive the Buy-Back price of $0.13 per share for shares accepted by the Company under the Buy-Back.

Shareholders who do not participate in the Buy-Back will retain their existing shareholdings. However, following completion of the Buy-Back, their percentage ownership of the Company may increase as a consequence of the reduction in the total number of shares on issue.

The Board does not expect the Buy-Back to have a material adverse effect on the Company's ability to pay its creditors.

2.7 Tax considerations

The tax consequences of participation in the Buy-Back will depend on the particular circumstances of each shareholder. The Company expects that the Buy-Back price will be treated as capital proceeds for Australian income tax purposes and does not presently expect any part of the Buy-Back Price to constitute a dividend.

Shareholders should seek their own independent taxation advice regarding the consequences of participating in the Buy-Back.

2.8 Relationship between Resolution 1 and Resolution 2

Resolution 1 and Resolution 2 are separate resolutions.

The Buy-Back is proposed as part of the arrangements associated with the proposed Delisting.

If Resolution 1 is approved, the Delisting may proceed regardless of whether Resolution 2 is approved.

The Buy-Back is conditional upon Resolution 1 being passed. Accordingly, the Buy-Back will only proceed if both Resolution 1 and Resolution 2 are approved by shareholders.

2.9 Voting Exclusion

Subject to section 2.5 above, there is no voting exclusion applicable to Resolution 2 and all shareholders are entitled to vote on Resolution 2.

Directors' Recommendation: *The Directors unanimously recommend that shareholders vote in favour of Resolution 2.*

3. Indicative timetable

The following indicative timetable is provided for shareholders’ information. All dates are subject to change, including to reflect any requirements imposed by ASX:

Event	Expected Timing
Announcement of proposed Delisting	23 July 2026
Dispatch of this Notice of Meeting	17 August 2026

Event	Expected Timing
Meeting to approve Delisting (Resolution 1) and Buy-Back (Resolution 2)	18 September 2026
Buy-Back offer opens (subject to approval of Resolution 2)	End of September 2026
Buy-Back offer closes	End of October 2026
Completion of Buy-Back / payment to participating shareholders	End of October 2026
Implementation of Unmarketable Parcel Facility	End of October 2026
Suspension from ASX quotation (at least 2 business days before Delisting)	Mid to late November 2026
Expected date of removal from ASX Official List	Late November 2026

Voting and proxies

1. Voting on a poll

On a poll, every member present in person or by attorney or by proxy (or, in the case of a body corporate, by representative) shall have one vote for each fully paid ordinary share held.

2. Proxies

(a) A Member entitled to attend and vote at the General Meeting is entitled to appoint a proxy to attend and vote instead of the Member.

(b) A Member entitled to attend and cast two or more votes at the General Meeting is entitled to appoint no more than two proxies.

(c) An instrument appointing a proxy must be in the form of the Proxy Form attached to this Notice of General Meeting.

(d) Where a Member appoints two proxies to vote at the General Meeting and the authority of one is not conditional on the other failing to attend or vote, each proxy must be appointed to represent a specified proportion of the Member's voting rights. If a Member appoints two proxies, the appointment is of no effect unless each proxy is appointed to represent a specified proportion or number of the Member's votes.

(e) A proxy need not be a Member of the Company.

(f) A proxy form may specify the manner in which the proxy is to vote in respect of a particular Resolution and, where a proxy form so provides, the proxy is not entitled to vote on the Resolution except as specified in the proxy form.

(g) An instrument appointing a proxy shall be deemed to confer authority to demand or join in demanding a poll.

(h) A proxy has the authority to vote on the Member's behalf as he or she thinks fit, on any motion to adjourn the General Meeting, or any other procedural motion, unless the Member gives a direction to the contrary.

(i) For an instrument of proxy deposited or received at the registered office of the Company in which the name of the proxy or the name of the office of the proxy in a proxy form is not filled in, the proxy of that Member is the chairperson of the General Meeting.

(j) Default appointment of the Chair. Where a Member completes a Proxy Form but does not name a proxy (or the named proxy does not attend or vote), the Member is taken to have appointed the Chair of the Meeting as the Member's proxy, to vote on the Member's behalf in accordance with any directions given on the Proxy Form or, in the absence of a direction, as the Chair sees fit.

(k) The chairperson of the General Meeting may require any person purporting to act as a proxy to establish to the satisfaction of the chairperson that the person has been validly appointed as a proxy and is the person named in the instrument of appointment, failing which the person may be excluded from attending or voting at the meeting.

(l) The authority of a proxy to speak and vote for a Member at the General Meeting is suspended while the Member is present at the meeting.

(m) To be valid, a proxy form must be signed by the Member or the Member's attorney or, if the Member is a corporation, executed in accordance with the corporation's constitution and the Corporations Act (and may be signed on behalf of the corporation by its attorney).

3. Where do I send my Proxy Form?

Proxy forms and authorities may be sent by post or email:

(a) By post – Automic, GPO Box 5193, Sydney NSW 2001

(b) By email – meetings@automicgroup.com.au

Given the unpredictable timing of postal delivery and the increased likelihood of unexpected delays, the Company strongly recommends any proxy forms are returned by email to ensure all forms are received by the deadline.

4. What if a proxy is appointed under a power of attorney?

If the Proxy Form is signed under a power of attorney on behalf of a Member, then the attorney must make sure that either the original power of attorney, or a certified copy, is sent with the Proxy Form unless the power of attorney has already been sighted by the Company.

5. What is the due date for appointing a proxy?

To be valid, the Proxy Form and the power of attorney or other authority (if any) under which it is signed (or an attested copy of it) must be received by not later than 10:00am (AEST) on 16 September 2026 being 48 hours prior to the General Meeting or before such other date if the General Meeting is adjourned.

TISSUE REPAIR

Proxy Voting Form

If you are attending the Meeting in person, please bring this with you for Securityholder registration.

Tissue Repair Ltd | ABN 20 158 411 566

Your proxy voting instruction must be received by **10:00am (AEST) on Wednesday, 16 September 2026**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: **https://investor.automic.com.au/#/home** Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.
Joint holding: Where the holding is in more than one name, all Shareholders should sign.
Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.
Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.
Email Address: Please provide your email address in the space provided.
By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at https://automicgroup.com.au.

Lodging your Proxy Voting Form:

Online
Use your computer or smartphone to appoint a proxy at
https://portal.automic.com.au/investor/home or scan the QR code below using your smartphone
Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.

BY MAIL:
Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:
Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:
meetings@automicgroup.com.au

BY FACSIMILE:
+61 2 8583 3040

All enquiries to Automic:
WEBSITE:
https://automicgroup.com.au

PHONE:
1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

STEP 1 - How to vote

APPOINT A PROXY:

I/We being a Shareholder entitled to attend and vote at the General Meeting of Tissue Repair Ltd, to be held at **10:00am (AEST) on Friday, 18 September 2026 at Level 5, Automic Group, 126 Phillip Street, Sydney NSW 2000** hereby:

Appoint the Chair of the Meeting (Chair) to vote in accordance with the following directions (or if no directions have been given, and subject to the relevant laws, as the Chair sees fit) at this meeting and at any adjournment thereof.

Please note: If you are not appointing the Chair of the Meeting as your proxy, please write in the box provided below the name of the person or body corporate you are appointing as your proxy. If the person so named is absent from the meeting, or if no person is named, the Chair will act on your behalf.

The Chair intends to vote undirected proxies in favour of all Resolutions in which the Chair is entitled to vote.
Unless indicated otherwise by marking the "for", "against" or "abstain" box you will be authorising the Chair to vote in accordance with the Chair's voting intention.

STEP 2 - Your voting direction

Resolutions		For	Against	Abstain
1	Approval of Removal from ASX Official List			
2	Approval of Off-Market Equal Access Share Buy-Back			

Please note: If you mark the abstain box for a particular Resolution, you are directing your proxy not to vote on that Resolution and your votes will not be counted in computing the required majority on a poll.

STEP 3 – Signatures and contact details

Individual or Securityholder 1	Securityholder 2	Securityholder 3
Sole Director and Sole Company Secretary	Director	Director / Company Secretary

Contact Name:

Email Address:

Contact Daytime Telephone

Date (DD/MM/YY)

/ /

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible).

AUTOMIC

TRP

+R TISSUE REPAIR

All Registry communications to:
Automic Group
GPO Box 5193
Sydney NSW 2001
Telephone (free call within Australia): 1300 288 664
ASX Code: TRP
Email: hello@automicgroup.com.au

17 August 2026

General Meeting of Shareholders

Dear Shareholder,

Tissue Repair Limited ACN 158411566 (ASX: TRP or "the **Company**"), advises the General Meeting will be held as a physical meeting at Automic Group, Level 5, 126 Phillip Street, Sydney NSW 2000 on 18 September 2026 at 10.00am (AEST) (**Meeting**).

Notice of Meeting
The Notice of Meeting and Explanatory Memorandum (**Notice**) for the Meeting is available online and can be viewed and downloaded by shareholders of the Company (**Shareholders**) from the Company's website at https://tissuerepair.com.au. or the Company's ASX market announcements platform at www.asx.com.au (ASX: TRP).

In accordance with sections 110C-110K of the Corporations Act 2001 (Cth) (as inserted by the Treasury Laws Amendment (2021 Measures No.1) Act 2021 (Cth), Shareholders will not be sent a hard copy of the Notice or Proxy Form unless Shareholders have already notified the Company that they wish to receive documents such as the Notice and Proxy Form in hard copy.

Voting by Proxy

Online scan the QR code below using your smartphone	Lodge your Proxy vote online at https://singleholding.automic.com.au/login by following the instructions: 1. Login to the Automic website using the holding details as shown on your holding statement. 2. Click on 'Meetings' - 'Vote'. To use the online lodgment facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown at the top of your holding statement.

For further information on the online proxy lodgement process, or if you require a hard copy Proxy Form, please contact the Company's Share Registry, Automic Registry Services (**Automic**), at hello@automicgroup.com.au or via phone on 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).

Shareholder queries in relation to the Meeting
Shareholders can contact the Company Secretary with any questions prior to the meeting via email at s.kejriwal@acclime.com.

Copies of all Meeting related material including the Notice, are available to download from the Company's website and the Company's ASX market announcements platform. In the event it is necessary or appropriate for the Company to make alternative arrangements for the Meeting, information will be provided to Shareholders via the ASX and the Company's website.

Authorised for ASX release by the Company Secretary.